opportunities to direct its development in a way that maximizes the power of the technology equitably and in a socially responsible manner. In this work, we apply automated mining of abstracts of genome editing publications in 2017 and part of 2018, focusing on the 2 main genome editing technologies--CRISPR/Cas and TALENs to infer the global distribution of genome editing research as a first step to identify emerging biases.
Results

General publication trends in genome editing
To obtain scientific publications on genome editing by CRISPR/Cas systems and TALENs, an automated search on PubMed followed by a download of abstracts was performed in the R programming language as described in the Methods section. A complete table of the number of articles  per journal is available in the Supplementary Table 1 and 2 . There was a positive correlation between the number of articles published on CRISPR and TALENs (Spearman correlation, r = 0.53, P = 1.5e--08). A small fraction of journals accounted for a large proportion of most genome editing articles (Figure 1) . Specifically, the top 50 journals for CRISPR genome editing in 2017 accounted for 48% of the articles (719 out 1521 articles). These journals constitute only 9.4% (50 out of 529 journals) of the total journals that published at least one article on CRISPR genome editing. A similar observation was made for publications on TALENs where 64% of the articles (93 out of 146 articles) were accounted for by 49% of the journals (50 out of 103 journals). These results show that genome editing publications are disproportionately distributed in a few journals including journals that require a subscription. 
Gender composition of authors in genome editing studies
Gender diversity is critical in advancing scientific discovery and overcoming health disparities. Yet, women are underrepresented in multiple fields of science and technology [7, 8] . Assessing gender diversity in emerging areas of technology could provide opportunities for addressing disparities before they become entrenched in society. To estimate the gender representation of male and female authors, the first names of authors was used to assign gender based on data from the US Social Security Administration baby names in the R package 'gender'. In 2017 for CRISPR genome editing, 43% of first authors were females while 57% were males. In contrast, when examining the last authors, conventionally the principal investigators, only 26% were females and the rest (74%) were males. The disparity between male and female authors was slightly lower when considering all authors of CRISPR genome editing papers irrespective of their positions in the author list (40% were females and 60% males). Authorship of papers on TALENs showed similar patterns: females were 42% of first authors, 28% of last authors and 40% of all authors. These results suggest that pre--existing gender biases in science and technology could be carried over to emerging technologies like genome editing. 
Genes, diseases and species targeted by genome editing studies
Identification of genes and diseases being investigated by genome editing technologies could help in the assessment of potential early clinical applications of the technology and highlight areas that may require new investment. Screening of the downloaded abstracts for gene names led to the retrieval of genes that are the focus of various genome editing studies. Genes were then ranked by the number of genome editing studies in which they appeared in the abstracts. The dystrophin gene (DMD) was the most frequently studied gene using CRISPR, followed by several cancer associated genes including P53 [9, 10] , Cystic Fibrosis Transmembrane Conductance (CFTR) gene [11, 12] , CXCR4--an HIV--1 entry co--receptor [13, 14] --and the hemoglobin B gene (HBB) important in sickle cell anemia and other hemoglobinopathies (Table  2) [15, 16] . CD4, an HIV--1 receptor [17] was the most studied gene for TALENs genome editing although there were only 2 articles. Another alternative approach for identifying diseases being targeted by genome editing technologies is using named entity recognition to extract disease names directly from abstracts. When this approach was applied to screen abstracts, the top diseases for CRISPR genome editing were cancer/tumor/carcinoma (355 articles), Duchenne Muscular Dystrophy (DMD, 24), malaria (14) , HIV/AIDS (18) and hepatitis B/C virus (13) . On the other hand, top diseases for TALENs were cardiovascular diseases (9 articles), HIV/AIDS (9), hepatitis B/C virus (8) and hemoglobinopathies (4 articles). [33-35, 16, 15] Interestingly, malaria, a disease that predominantly affects sub--saharan Africa is one of the top diseases for CRISPR research although researchers from the region are heavily underrepresented in the field. While Africa is underrepresented in several areas of research besides genome editing, underrepresentation in genome editing is crucial as the technology has a great potential in malaria eradication but also poses broader ethical issues [36, 37] . An understanding of species that are research targets of genome editing technologies could help identify neglected species by the emerging technology. Therefore, we extracted words referring to various species from the abstracts. Among the top species of interest in genome editing research using CRISPR, humans were the most common (519 articles), followed by mice (306), yeast (S. cerevisiae, 76), zebrafish (60), rice (40) , pigs (34), drosophila (32), HIV (28) , and Caenorhabditis elegans (27) . Similarly, for TALENs, human cells were the most commonly studied (38 articles), mice (22) , zebrafish (10), rat (10), pigs (9), rice (5) and wheat (5) . Discussion Genome editing technologies could revolutionize treatment of several diseases and open new ways for engineering biological organisms for medical and non--medical applications. An understanding of the global distribution of genome editing research could inform policy development, funding strategies and identify research biases that could lead to disparities in the application of the technology. Unfortunately, with thousands of papers being published in the field, manual curation of their content is not optimal. Automated approaches to mining literature could fill this gap by providing an unbiased and rapid assessment of progress in the field. However, there are several drawbacks to applying automated literature--mining approaches. First, mining of published literature cannot capture all research. For example, proprietary research in commercial companies is often not published. Furthermore, even in academia, research may not always be published immediately. Secondly, many publications are behind paywalls thereby limiting literature mining to only abstracts. Finally, computational approaches for mining text using natural language processing (NLP) and machine learning are still not able to cope with the complexity ambiguity and diversity of human language. In this work, literature mining of genome editing publications shows that the development of the technology disproportionately occurs in the US and China. While the US leads in CRISPR based studies, China leads in TALENs. Thus, these two nations may potentially be the first to see significant benefits of genome editing technologies. While today no clinical applications have been approved for genome editing technologies, the technology could provide early economic benefits such as new careers especially for the researchers needed to develop the technology. It is conceivable that regions of the world already leading research in this area will be well positioned with the human capacity required to advance it which will result in disproportionate economic gains. Regions of the world such as Africa that are underrepresented in research in this field will left behind and may not be able to catch up. Genome editing research is not immune to entrenched biases that exist in our society today. In particular, gender biases in science and technology could bias the development of genome editing technologies. However, the relatively recent emergence of the field compared to other areas of technology provides a unique window of opportunity that should be used to avoid new biases and address those inherited from related fields. The results presented in this work show that while there are 60% male and 40% female researchers in this field based on publications, the principal investigators are predominantly male (76%) which is consistent with observations that women are even more underrepresented in leadership roles in Science, Technology, Engineering, Mathematics and Medicine (STEMM) fields [38] . The disproportionate development of genome editing technologies towards a select number of diseases, genes and animals or plants is also notable. It is encouraging that among the top diseases where genome editing research is ongoing are rare diseases such as Duchenne Muscular Dystrophy [19] and those that predominantly afflict some of the poorest regions of the world such as malaria [37, 39] . Unfortunately, in the case of malaria, researchers based in areas affected by the disease (sub--Saharan Africa) are highly underrepresented in genome editing research. This misalignment needs to be addressed because objective assessment of the safety, ethical and economic issues arising from genome editing technologies will require regulatory approvals by local experts and will directly impact local communities. Furthermore, a significant number of genome editing publications are in subscription journals and may be inaccessible to researchers in poorer regions of the world making it harder for them to compete in the field. Proactive engagement of researchers in areas where field applications such as mosquito gene drives will be deployed occur using genome editing technologies will be crucial [36] . One such partnership is the Target Malaria consortium that brings together various stakeholders including researchers and risk--assessment specialists from Europe and Africa [40] . Genome editing is a powerful technology. Its disproportionate development by a few researchers, regions of the world or in a gender--biased manner will limit its full potential. Furthermore, its disproportionate application to select genes, diseases and organisms could limit its capacity as an aid for deepening our understanding of basic biological processes across various organisms, engineering new biological systems for food or industrial purposes and eventually finding cures to several diseases.
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Materials and Methods
Data retrieval
To download abstracts of publications on genome editing, the PubMed literature database was queried on May 21 st 2018 using the 'easyPubMed' package in R. Briefly, the PubMed database was queried using 4 search queries independently, two for CRISPR/Cas based genome editing and two for TALENs based genome editing. To obtain genome editing publications involving CRISPR/Cas systems in 2017 the in the search term used was "CRISPR genome editing AND (2017[PDAT])" while to download genome editing publications involving CRISPR/Cas systems in 2018, the search term used was "CRISPR genome editing AND (2018[PDAT])". Abstracts on TALENs based genome editing were downloaded using the search terms "TALENs genome editing AND (2017[PDAT])" for publications in 2017 and "TALENs genome editing AND (2018[PDAT])" for publications in 2018. Because CRISPR research does not always involve genome editing, these numbers capture only the subset of papers where the abstracts explicitly mention genome editing. Abstracts were downloaded in XML format to allow further retrieval of metadata such as author names, institutional affiliations, addresses and countries. Analysis of author names, gender and institutional affiliations Author names, journals and institutional addresses were directly extracted from the downloaded XML abstracts using the R package 'easyPubMed'. Authors were assigned a gender using data from the US Social Security Administration baby names as implemented in the R package 'gender'. Institutional addresses were further processed to identify country names using the R package 'map'. 
